Hepatology - European Medical Journal

This site is intended for healthcare professionals

Continue

Hepatology

Filter
3 Jun 2026

Immune Side Effects Linked to Better Survival in Biliary Tract Cancer

Imaging-detected immune-related adverse events may help predict improved survival in patients with advanced biliary tract cancer receiving durvalumab-based chemotherapy.
30 May 2026

WHO Steatotic Liver Disease Resolution Marks Global Policy Shift

The World Health Assembly has formally recognised liver disease within the global NCD agenda, prompting calls for national action and accountability.
29 May 2026

EASL 2026: Hepatitis C Testing Barriers Delay Early Treatment

Experts at EASL 2026 discussed persistent barriers in hepatitis C testing, including delayed diagnosis, reinfection monitoring, and limited point-of-care access.
28 May 2026

EASL 2026: 'Natural' Wellness Supplements Linked to Liver Injury

Experts at EASL 2026 warned that supplement-induced liver injury is rising alongside the global wellness and herbal supplement boom.
27 May 2026

EASL 2026: Alcohol Policy Efforts Sharpen Focus on Liver Disease Harm

Alcohol policy and liver disease prevention were discussed at EASL 2026, with experts highlighting alcohol’s wider health burden across Europe.
27 May 2026

Textbook Outcome Achievable in Complex Liver Surgery

Textbook Outcome was achieved in more than one-third of patients undergoing complex liver surgery with vascular reconstruction.
24 May 2026

Immunosuppressive Therapy May Drive AIH Recompensation

Patients with autoimmune hepatitis (AIH) and decompensated cirrhosis achieved AIH recompensation following immunosuppressive therapy in a retrospective cohort study.
RAAS Inhibitors Lower Liver Cancer Risk in MASLD - EMJ
22 May 2026

RAAS Inhibitors in MASLD Linked to Lower Liver Cancer Risk

RAAS inhibitor use in MASLD is linked to lower hepatocellular carcinoma risk in a large Taiwan cohort. Find out more from the study findings.
We’ve noticed you’re accessing
from North/South America.